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ApoptosisAbstract We designed new pyrazole derivatives as inhibitors of the cell cycle kinases and devel-
oped a simple environmentally sustainable synthesis process. We synthesized the pyrazolyl thiourea
derivatives using rapid ultrasound mediated methods and confirmed their structures by NMR and
IR spectra. The apoptosis and necrosis inducing effects of the new compounds were investigated.
Cell cycle analysis and expression of genes involved in apoptosis, cell cycle and xenobiotic
metabolism were studied. The compounds presented modest apoptotic effects in human cancer cells.
The N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]carbamothioyl]-4-chloro-benzamide compound (4e)
induced a significant increase of cells in G2/M phases in conjunction with an increased expression
of cyclin A and cyclin B, emerging as a promising anticancer drug, to be further developed in animal
models of cancer.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In malignant cells the initiation, progression, and completion of the
cell cycle are frequently altered inducing an abnormal growth
(Shapiro and Harper, 1999). A broad range of compounds are
designed to interrupt cell cycle progression in order to control the
growth of cancer cells. The compounds capable to arrest the cell cycle
rely on various mechanisms of action. Some of the key mechanisms
responsible for cell cycle progression and cell division, include thehibitors.
2 G.M. Nitulescu et al.cyclin-dependent kinases (CDKs), checkpoint kinases (CHKs) and
Aurora kinases (AURs), all being important targets in anticancer drug
discovery (Pitts et al., 2014).
The pyrazole ring emerged as a powerful scaffold used extensively
in the design of compounds targeted to block the cell cycle progression
in cancer cells (Keter and Darkwa, 2012). Pharmacologic inhibitors of
cyclin-dependent kinases (CDKs) have been shown to block cell cycle
progression in a large variety of cell types. The use of the pyrazole ring
in the design of CDKs inhibitors is demonstrated by the development
of AT7519, a 4-[(2,6-dichlorobenzoyl)amino-1H-pyrazole-3-carbox
amide derivative, with anti-proliferative effects in leukemia, colon
and breast cancer (Sa´nchez-Martı´nez et al., 2015). A series of 4-
arylazo-3,5-diamino-1H-pyrazole derivatives demonstrated anti-CDK
kinase activities and anti-proliferative properties (Jorda et al., 2015).
Aurora kinases are important targets for cancer chemotherapy
because of their role in the cell division, especially during mitosis
and many inhibitors are currently under development (Kollareddy
et al., 2012). AT9283 is a pyrazol-4-yl urea derivative and a potent
AUR A and B inhibitor, capable of inhibiting growth and survival
of multiple solid tumor and leukemia cell (Kimura, 2010). The impor-
tance of the pyrazole template in the design of AURs inhibitors had
been demonstrated (Nitulescu et al., 2014) and can be observed in
the development of both isoform non-selective inhibitors, such as
SCH 1473759 (Yu et al., 2010) and ABT-348 (Curtin et al., 2012),
and subtype selective inhibitors. Tozasertib and its derivative
ENMD-2076 are based on the 3-aminopyrazole scaffold and are
potent inhibitors of AUR A (Nitulescu et al., 2013), while AZD1152
and GSK1070916 are pyrazole derivatives designed as AUR B selective
inhibitors (Zhang et al., 2010).
CHKs are key regulators of cell cycle progression serving to main-
tain the genomic integrity of cells and there is a significant effort to
design selective inhibitors (Pitts et al., 2014). MK-8776 is a 1-methyl-
1H-pyrazol-4-yl-pyrazolo[1,5-a]pyrimidine derivative selective CHKs
inhibitor that interacts synergistically with DNA antimetabolite agents
inducing cell death in tumor cells (Guzi et al., 2011). PF-00477736 is
also a 1-methyl-1H-pyrazol-4-yl CHK1 inhibitor which was demon-
strated to enhance the cytotoxicity of clinically important chemother-
apeutic agents and radiation (Blasina et al., 2008).
In our previous research, we designed and developed several com-
pounds with anti-proliferative effects by coupling the pyrazole scaf-
fold and the thiourea moiety (Nitulescu et al., 2013). This strategy
of combining the pyrazole ring and the thiourea moiety proved to
be successful in the development of various anti-proliferative agents
(C¸alıskan et al., 2013; Karipcin et al., 2013) and apoptosis inducing
agents (Nitulescu et al., 2015). Several acyl thiourea derivatives con-
taining pyrazole ring were evaluated and demonstrated very good
anticancer properties on human leukemia, colon, and liver cancer cell
lines (Koca et al., 2013) by inhibiting human AURs (Ozgur et al.,
2015). The thiourea and pyrazole ring were used for the design of
several cell cycle inhibitors targeting CDK 2, 4 and 6 (Sun et al.,
2013).
Based on the biopharmaceutical profiling of our previously synthe-
sized pyrazole derivatives (Anuta et al., 2014), in this work we devel-
oped new compounds by joining the pyrazole and thiourea
substructures, in order to target the cell cycle kinases.
2. Methods
2.1. Chemistry
All reagents and solvents were obtained from common com-
mercial suppliers and used without purification. The acetoni-
trile was dried over 3 A˚ molecular sieves and distillated. All
reactions were followed by thin-layer chromatography analysis
on silica gel 60F254 aluminum sheets, mobile phase toluene:Please cite this article in press as: Nitulescu, G.M. et al., Ultrasound-assisted synthes
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Melting points (mp) were measured in open glass capillaries
on an IA9000 Series melting point apparatus (Electrothermal,
UK) and are uncorrected. The IR spectra were recorded on a
JASCO FT/IR-4200 spectrometer (JASCO, Japan) with an
ATR PRO450-S accessory. The elemental analyses were per-
formed on a Series II 2400 CHNS/O Analyzer (Perkin Elmer,
USA). The synthesis were performed using an Elmasonic S15H
ultrasonic equipment operating at 37 kHz (Elma Hans Sch-
midbauer GmbH & Co., Singen, Germany).
The NMR spectra were performed in DMSO-d6 on a Gem-
ini 300BB instrument (Varian, USA) operating at 300 MHz for
1H and 75 MHz for 13C. The chemical shifts were recorded as d
values in ppm units downfield to tetramethylsilane, used as
internal standard. The coupling constants values (J) are
reported in hertz (Hz) and the splitting patterns are abbrevi-
ated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m,
multiplet.
2.1.1. General synthesis procedure for compounds 4a–h
A solution of 4-substituted benzoic acid (0.1 mol) in anhy-
drous 1,2-dichlorethane is refluxed with thionyl chloride
(14.5 mL, 0.2 mol) until evolution of gas is completed. The sol-
vent and the excess thionyl chloride are removed by distillation
at reduced pressure. The obtained 4-substituted benzoyl chlo-
ride (10 mmol) is dissolved in acetonitrile (10 mL) and ammo-
nium thiocyanate (10 mmol) is added. The mixture was
sonicated for 15 min at room temperature and 37 kHz. The
resulting ammonium chloride was removed by filtration and
the suitable aminopyrazole (10 mmol) was added to the raw
benzoyl isothiocyanate solution. The mixture was subjected
to ultrasonic irradiation for 15–30 min and then poured into
50 mL of 0.1 M hydrochloric solution. The compounds (4a–
h) were recrystallized from isopropanol.
2.1.1.1. 4-chloro-N-[[3-(4-fluorophenyl)-1H-pyrazol-5-yl]car-
bamothioyl]benzamide (4a). Yield 77%, mp 234–235 C. IR
(cm1): 3166 (NAH), 3029 (NAH), 1667 (C‚O), 1537
(CAN). 1H NMR (DMSO-d6, ppm): 13.25 (s, 1H, NH),
12.75 (s, 1H, ACSANHA), 11.75 (s, 1H, ACOANHA), 7.92
(d, J= 8.6 Hz, 2H, ArH), 7.73 (dd, J= 8.9 Hz, J= 5.2 Hz,
2H, ArH), 7.54 (d, J= 8.6 Hz, 2H, ArH), 7.38 (s, 1H, Pyrz),
7.34 (t, J= 8.9 Hz, 2H, ArH). 13C NMR (DMSO-d6, ppm):
177.01 (ACSA), 167.74 (ACOA), 163.66 (1JC–F = 263.9 Hz),
147.70 (Pyrz), 141.06 (Pyrz), 138.11, 130.92, 129.11, 128.91,
127.32 (3JC–F = 8.0 Hz), 125.65, 116.08 (
2JC–F = 21.5 Hz),
95.75 (Pyrz). Calcd. for C17H12ClFN4OS: C, 54.48; H, 3.23;
N, 14.95; S, 8.5; Found: C, 54.55; H, 3.27; N, 15.00; S, 8.61%.
2.1.1.2. N-[[3-(4-fluorophenyl)-1H-pyrazol-5-yl]carbamoth-
ioyl]-4-methyl-benzamide (4b). Yield 69%, mp 243–245 C.
IR (cm1): 3166 (NAH), 3016 (NAH), 1664 (C‚O), 1534
(CAN). 1H NMR (DMSO-d6, ppm): 13.30 (s, 1H, NH),
13.25 (s, 1H, ACSANHA), 11.60 (s, 1H, ACOANHA), 7.92
(d, J= 8.3 Hz, 2H, ArH), 7.73 (dd, J= 8.9 Hz, J= 5.2 Hz,
2H, ArH), 7.46 (s, 1H, Pyrz), 7.34 (t, J= 8.9 Hz, 2H, ArH),
7.30 (d, J= 8.3 Hz, 2H, ArH), 2.27 (s, 3H, CH3).
13C NMR
(DMSO-d6, ppm): 177.21 (ACSA), 168.53 (ACOA), 162.07
(1JC–F = 254.4 Hz), 147.78 (Pyrz), 144.41, 143.84 (Pyrz),is and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors.
New pyrazole derivatives as cell cycle inhibitors 3129.11, 129.00, 128.91, 127.39 (3JC–F = 8.0 Hz), 125.71, 116.12
(2JC–F = 22.0 Hz), 95.80 (Pyrz), 21.21 (CH3). Calcd. for
C18H15FN4OS: C, 61.00; H, 4.27; N, 15.81; S, 9.05; Found:
C, 61.06; H, 4.31; N, 16.02; S, 8.88%.
2.1.1.3. 4-chloro-N-[[3-(4-chlorophenyl)-1H-pyrazol-5-yl]car-
bamothioyl]benzamide (4c). Yield 71%, mp 234–235 C. IR
(cm1): 3155 (NAH), 3098 (NAH), 1668 (C‚O), 1558
(CAN). 1H NMR (DMSO-d6, ppm): 13.24 (s, 1H, NH),
13.06 (s, 1H, ACSANHA), 11.80 (s, 1H, ACOANHA), 8.00
(d, J= 8.5 Hz, 2H, ArH), 7.78 (d, J= 8.2 Hz, 2H, ArH),
7.61 (d, J= 8.5 Hz, 2H, ArH), 7.53 (d, J= 8.2 Hz, 2H,
ArH), 7.50 (s, 1H, Pyrz). 13C NMR (DMSO-d6, ppm):
177.07 (C‚S), 167.74 (C‚O), 147.75 (Pyrz), 138.12 (Pyrz),
132.95, 130.92, 130.76, 129.16, 128.55, 127.85, 126.90, 96.07
(Pyrz). Calcd. for C17H12Cl2N4OS: C, 52.18; H, 3.09; N,
14.32; S, 8.19; Found: C, 52.19; H, 3.20; N, 14.47; S, 8.02%.
2.1.1.4. N-[[3-(4-chlorophenyl)-1H-pyrazol-5-yl]carbamoth-
ioyl]-4-methyl-benzamide (4d). Yield 67%, mp 243–245 C.
IR (cm1): 3159 (NAH), 3097 (NAH), 1662 (C‚O), 1528
(CAN). 1H NMR (DMSO-d6, ppm): 13.37 (s, 1H, NH),
13.20 (s, 1H, ACSANHA), 11.59 (s, 1H, ACOANHA), 7.92
(d, J= 8.4 Hz, 2H, ArH), 7.79 (d, J= 8.6 Hz, 2H, ArH),
7.54 (d, J= 8.6 Hz, 2H, ArH), 7.51 (s, 1H, Pyrz), 7.35
(d, J= 8.4 Hz, 2H, ArH), 2.39 (s, 3H, CH3).
13C NMR
(DMSO-d6, ppm): 177.24 (C‚S), 168.53 (C‚O), 143.76
(Pyrz), 140.74 (Pyrz), 132.87, 129.10, 129.02, 128.95, 128.81,
127.84, 126.83, 96.02 (Pyrz), 21.14 (CH3). Calcd. for
C18H15ClN4OS: C, 58.30; H, 4.08; N, 15.11; S, 8.65; Found:
C, 58.08; H, 4.02; N, 15.19; S, 8.60%.
2.1.1.5. N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]carbamoth-
ioyl]-4-chloro-benzamide (4e). Yield 70%, mp 234–235 C.
IR (cm1): 3165 (NAH), 3027 (NAH), 1667 (C‚O), 1539
(CAN). 1H NMR (DMSO-d6, ppm): 13.30 (s, 1H, NH),
12.86 (s, 1H, ACSANHA), 11.80 (s, 1H, ACOANHA), 8.00
(d, J= 8.5 Hz, 2H, ArH), 7.72 (d, J= 8.5 Hz, 2H, ArH),
7.67 (d, J= 8.5 Hz, 2H, ArH), 7.61 (d, J= 8.5 Hz, 2H,
ArH), 7.50 (s, 1H, Pyrz). 13C NMR (DMSO-d6, ppm):
177.16 (C‚S), 167.79 (C‚O), 147.79 (Pyrz), 138.13 (Pyrz),
134.71, 132.08, 130.78, 130.22, 130.19, 128.56, 127.17, 121.57,
96.05 (Pyrz). Calcd. for C17H12BrClN4OS: C, 46.86; H, 2.78;
N, 12.86; S, 7.36; Found: C, 46.79; H, 2.83; N, 12.92; S, 7.33%.
2.1.1.6. N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]carbamoth-
ioyl]-4-methyl-benzamide (4f). Yield 75%, mp 243–245 C.
IR (cm1): 3155 (NAH), 3094 (NAH), 1667 (C‚O), 1528
(CAN). 1H NMR (DMSO-d6, ppm): 13.37 (s, 1H, NH),
12.97 (s, 1H, ACSANHA), 11.57 (s, 1H, ACOANHA), 7.91
(d, J= 8.3 Hz, 2H, ArH), 7.71 (d, J= 8.6 Hz, 2H, ArH),
7.67 (d, J= 8.6 Hz, 2H, ArH), 7.48 (s, 1H, Pyrz), 7.35 (d,
J= 8.3 Hz, 2H, ArH), 2.39 (s, 3H, CH3).
13C NMR
(DMSO-d6, ppm): 177.42 (C‚S), 168.67 (C‚O), 143.94
(Pyrz), 139.03 (Pyrz), 132.17, 132.14, 132.08, 129.21, 128.93,
128.80, 127.22, 121.58, 96.15 (Pyrz), 21.26 (CH3). Calcd. for
C18H15BrN4OS: C, 52.06; H, 3.64; N, 13.49; S, 7.72; Found:
C, 51.91; H, 3.62; N, 13.63; S, 7.85%.
2.1.1.7. 4-chloro-N-[(1,5-dimethyl-3-oxo-2-phenyl-pyrazol-4-
yl)carbamothioyl]benzamide (4g). Yield 83%, mp 190–
192 C. IR (cm1): 3132 (NAH), 3082 (NAH), 1670 (C‚O),Please cite this article in press as: Nitulescu, G.M. et al., Ultrasound-assisted synthes
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11.82 (s, NH), 11.51 (s, NH), 7.99 (d, J= 8.5 Hz, 2H), 7.61
(d, J= 8.5 Hz, 2H), 7.52 (t, J= 7.8 Hz, 2H), 7.38–7.32 (m,
3H, ArH), 3.12 (s, 3H, CH3), 2.21 (s, 3H, CH3).
13C NMR
(DMSO-d6, ppm): 181.95 (C‚S), 167.30 (C‚O), 161.10
(C‚O), 153.12 (Pyrz), 138.05, 135.03, 131.02, 130.74, 129.18,
128.56, 126.56, 123.91, 108.28 (Pyrz), 35.71 (CH3), 11.53
(CH3). Calcd. for C19H17ClN4O2S: C, 56.93; H, 4.27; N,
13.98; S, 8.00; Found: C, 57.11; H, 4.19; N, 14.14; S, 7.97%.
2.1.1.8. N-[(1,5-dimethyl-3-oxo-2-phenyl-pyrazol-4-yl)car-
bamothioyl]-4-methyl-benzamide (4h). Yield 76%, mp 203–
204 C. IR (cm1): 3165 (NAH), 3013 (NAH), 1671 (C‚O),
1645 (C‚O), 1524 (CAN). 1H NMR (DMSO-d6, ppm):
11.83 (s, NH), 11.63 (s, NH), 7.89 (d, J= 8.3 Hz, 2H), 7.52
(dd, J= 8.5 Hz, J= 1.6 Hz, 2H), 7.38–7.32 (m, 5H, ArH),
3.11 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.20 (s, 3H, CH3).
13C
NMR (DMSO-d6, ppm): 182.28 (C‚S), 168.22 (C‚O),
161.15 (C‚O), 153.11 (Pyrz), 143.77, 135.00, 129.20, 128.86,
129.24, 129.14, 126.63, 123.96, 108.32 (Pyrz), 35.71 (CH3),
21.21 (CH3), 11.55 (CH3). Calcd. for C20H20N4O2S: C,
63.14; H, 5.30; N, 14.73; S, 8.43; Found: C, 63.30; H, 5.21;
N, 14.87; S, 8.33%.
2.2. Evaluation of biological activity
Human colorectal adenocarcinoma HT-29 (ATCC HTB-38)
and acute monocytic leukemia THP-1 (ATCC TIB-202) cell
lines were used. The adherent cell cultures were maintained
in Dulbecco’s Modified Essential Medium (DMEM) (Sigma,
USA) supplemented with 10% heat-inactivated fetal bovine
serum (Sigma, USA) at 37 C, 5% CO2, in a humid atmo-
sphere. The monocytic cell culture, THP-1, was maintained
in RPMI-1640 medium (Sigma, USA) and 10% fetal bovine
serum.
2.2.1. Cell viability assay
The HT-29 cells were seeded into 96-well plates at 5  103 cells/
well and after 24 h, binary dilutions of each compound were
added and the cells were maintained for other 24 h at 37 C,
5% CO2, in a humid atmosphere. 5  103 THP-1 cells were
added to binary dilutions of each compound and were main-
tained 24 h at 37 C, 5% CO2, in a humid atmosphere. The cell
viability was evaluated using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega) measuring the
absorbance at 490 nm in an ELISA reader.
2.2.2. Flow cytometry analysis of cellular apoptosis
Apoptosis detection was made using Annexin V-FITC Apop-
tosis Detection Kit I (BD Bioscience Pharmingen, USA)
according to manufacturer protocol. For this purpose,
3  105 HT-29 cells were seeded in 3.5 cm diameter wells and
treated with 50 lg/mL of the tested compounds for 24 h. Both
adherent and detached cells were re-suspended in 100 lL of
binding buffer and stained with 5 lL Annexin V-FITC and
5 lL propidium iodide for 10 min in dark. At least 10,000
events from each sample were acquired using a Beckman Coul-
ter EPICS XL flow cytometer (Fullerton, CA, USA). The per-
centage of treatment-affected cells was determined by
subtracting the percentage of apoptotic/necrotic cells in the
untreated population from percentage of apoptotic cells inis and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors.
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itive and PI negative, and late apoptosis, as Annexin V and PI
positive.
2.2.3. Flow cytometry analysis of cell cycle
After treatment with 50 lg/mL of tested compounds for 24 h,
the cells were harvested, washed in cold solution of PBS (pH
7.5), and then fixed in cold 70% ethanol and stored at
20 C overnight. Samples were centrifuged, washed with
PBS and then re-suspended in 100 ll PBS, treated with RNase
A (1 mg/mL) and stained with propidium iodide (100 lg/mL),
at 37 C for 1 h. The DNA content of cells was quantified on a
Beckman Coulter EPICS XL flow cytometer (Fullerton, CA,
USA) and analyzed using FlowJo 8.8.6 software (Ashland,
Oregon, USA).
2.2.4. Quantification of the expression of genes involved in
apoptosis, cell cycle and xenobiotic metabolism
Total RNA was extracted with Trizol Reagent (Invitrogen,
USA) according to the manufacturer’s protocol from HT-29
cells treated for 24 h with tested compounds (10 lg/mL,
50 lg/mL). The concentration and purity of the RNA samples
were determined using Nanodrop equipment. For each sam-
ple, 2 lg of total RNA was used for reverse transcription with
High Capacity cDNA Reverse Transcription Kit with RNase
inhibitor (Applied Biosystem), and 50 ng cDNA from each
sample was used in real-time PCR reaction. Real-Time PCR
was performed on an ABI 7300 Real-Time PCR System using
pre-validated Taqman Gene Expression Assays kits (Applied
Biosystems). Human beta-actin was used as endogenous con-
trol. Each experiment was performed three times. Results were
analyzed with RQ study software (Applied Biosystems). The
DDCT method was used to compare the relative gene expres-
sion levels.
3. Results and discussion
3.1. Chemistry
Numerous investigations now routinely use non-traditional
synthetic methodologies such as ultrasound mediated synthesis1
a b
32
R1R1R1
C
C
S
N O
C
Cl O
C
OH O
Scheme 1 Reagents: (a) SOCl2, C2H4Cl2, reflux; (b) NH4SCN, CH3
ultrasonic irradiation; (d) C11H11N2–NH2, CH3CN, ultrasonic irradia
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able processes we optimized the synthesis of the acylthiurea
derivatives and reduced the energy consumption by the use
of ultrasounds.
The 1H-pyrazol-5-ylthiourea and (1,5-dimethyl-3-oxo-2-p
henyl-pyrazol-4-yl)thiourea derivatives were synthesized using
the method presented in Scheme 1 starting from 4-substituted
benzoic acids (1) that were treated with thionyl chloride to
yield the corresponding 4-substituted benzoyl chlorides (2).
The ultrasound-assisted reaction of 4-R-benzoyl chlorides with
ammonium isothiocyanate in acetonitrile afforded the corre-
sponding 4-R-benzoyl isothiocyanates (3). The sonication of
3 with suitable aminopyrazoles afforded the target compounds
(4a–h).
The structures of the synthesized compounds were con-
firmed by NMR and IR spectral data. In the infrared spectra
of compounds 4a–h, can be observed the absorptions between
3166 and 3013 cm1 relating to the thiourea NHs stretch and
the absorptions in the 1645–1670 cm1 range produced by
the carbonyl bond stretching. The CAN bond of the acyl
thiourea moiety has an intense band in the range 1566–
1521 cm1. The band has unexpectedly high intensity com-
pared with amides, explaining the involvement of the carbonyl
group in an intra-molecular hydrogen bond.
In the 1H NMR spectra of the compounds 4a–f the hydrogen
of the pyrazole ring presents one singlet at 13.37–13.24 ppm,
the thiourea hydrogen atoms give two broad singlets
at 13.25–12.75 ppm (NHAC‚S) and 11.80–11.59 ppm
(NHAC‚O), and the hydrogen on the two phenyl groups
can be observed in the range of 8.00–7.30 ppm. The methyl
substituted compounds present a singlet in range of 2.39–
2.27 ppm. The structure of the compounds 4g–h is confirmed
by the broad singlets of the thiourea moiety at 11.82–
11.63 ppm (NHAC‚S) and 11.63–11.51 ppm (NHAC‚O),
the signals of the hydrogen on the benzene rings observed in
the range of 7.99–7.32 ppm, and the two methyl groups at
3.12–3.11 ppm and 2.21–2.20 ppm.
In the 13C NMR spectra of the compounds 4a–f are
observed a signal in the range of 177.42–177.01 ppm is related
to the thiourea carbon (C‚S), a signal at 168.67–167.74 ppm
assignable to the carbonyl (C‚O), and the pyrazole ring sig-
nals at 147.83–143.40 ppm (C-3), 96.15–95.75 ppm (C-4) and4h, R1= CH34g, R1= Cl
c
4e, R1= Cl, R2= Br
4b, R1= CH3, R2= F
d
4a, R1= Cl, R2= F
4c, R1= Cl, R2= Cl
4f, R1= CH3, R2= Br
4d, R1= CH3, R2= Cl
R1
R2
R1
N
H
N
N
H
C
C
O
N
HS
N
O
N
CH3
CH3
N
H
C
C
O
N
HS
CN, ultrasonic irradiation; (c) R2–C6H4–C3H2N2–NH2, CH3CN,
tion.
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Table 1 Percentage of cells undergoing apoptosis and necrosis
in HT-29 cells treated for 24 h with 50 lg/mL pyrazole
derivatives. Apoptosis/necrosis was measured by flow cytom-
etry using the Annexin V-PI test.
Sample Necrosis Early
apoptosis
Late
apoptosis
Viable
cells
Control 1.02 2.26 0.11 96.6
4a 1.66 1.64 0.15 96.5
4b 1.62 1.56 0.04 96.8
4c 0.87 3.01 0.22 95.9
4d 1.82 2.13 0.27 95.8
4e 8.43 5.69 1.16 84.7
4f 2.66 2.67 0.84 93.8
4g 1.12 6.95 0.54 91.4
4h 1.02 4.66 0.14 96.8
New pyrazole derivatives as cell cycle inhibitors 5143.84–138.13 ppm (C-5). The methyl group presented a signal
in the range of 21.26–21.14 ppm. In the 13C NMR spectra of
the compounds 4g–h we can observe the C‚S carbon signal
at 182.28–181.95 ppm, the carbonyl carbon at 168.22–
167.30 ppm and the signals of the methyl groups at
35.71 ppm and 11.55–11.54 ppm.
The compound’s purity was certified by elemental analyses
and the results were within ± 0.4 of the theoretical values
3.2. Evaluation of biological activity
3.2.1. Cell viability assay
Anticancer drugs are designed to kill selectively tumor cells. At
the primary screening stage, in vitro toxicity assay was assessed
using CellTiter 96 AQueous One Solution Cell Proliferation
Kit (Promega, USA). The pyrazole antitumor activity was
tested using adherent HT29 cells and suspension monocyte line
THP1. The THP1 line was more susceptible to the action of
synthesized compounds. The viability of THP1 cells, grown
in the presence of 50 lg/ml pyrazole, decreased in all cases,
and the toxic effects were manifested to a concentration of
25 lg/ml in the case of 4e (Fig. 1). IC50 of the compound 4e
was 40.34, comparing with other compounds whose IC 50
was included in the range 42.97–48.96.
3.2.2. Analysis of cellular cytotoxicity by flow cytometry
The apoptosis- and necrosis-inducing effects of the compounds
were tested in HT-29 cells using propidium iodide (PI) in con-
junction with Annexin-V-FITC. The tested compounds pro-
duced only modest effects on apoptosis/necrosis induction.
The compound 4e has the highest necrosis-inducing effect,
while compound 4g has the highest apoptosis-inducing effect
(Table 1).
Flow cytometry diagrams of apoptosis/necrosis effects in
HT-29 cells treated for 24 h with 4a–h compounds are pre-
sented (Fig. 2). Dot plots are representation of logarithmic
Annexin V fluorescence versus PI fluorescence. The cells in
region Q4 represent living cells, Q3 early apoptotic cells, Q2
late apoptotic cells and Q1 those in necrosis.Figure 1 Results of THP1 cells viability (%) after 24 h exposure t
compounds using the MTS assay.
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In order to identify the mechanism of apoptosis, we performed
real-time PCR analysis for expression of genes implicated in
apoptosis. It was observed that treatment of HT-29 cells with
50 lg/ml of 4 g and 4 h induced inhibition in Bax and MCL1
pro-apoptotic genes expression. Furthermore, inhibition of
expression of caspases 8 was observed in the presence of
50 lg/ml of 4 h suggesting extrinsic apoptotic pathway inhibi-
tion and increases in expression level of caspase 9 and caspase
3 (slightly) was associated with activation of intrinsic pathway.
After 24 h, all other compounds induced an increase in the
pro-apoptotic gene expression of extrinsic /intrinsic pathways
(Fig. 3).
3.2.4. Flow cytometry analysis of cell cycle
Analyses of the cell cycle distribution of HT-29 cells after
exposure for 24 h to 50 lg/mL of each newly synthesized pyra-
zole derivatives showed different modification patterns
depending on the chemical structure (Fig. 4, Table 2). The
5-aminopyrazole derivatives (4a–f) increased the G2/M,o 6.25 lg/mL, 12.5 lg/mL, 25 lg/mL, and 50 lg/mL of the new
is and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors.
Figure 2 Flow cytometry diagram of double-staining with Annexin V-FITC/PI after treatment with 50 lg/mL of the new compounds.
Figure 3 The effects exerted by the new compounds (50 lg/mL) on the expression of apoptotic genes. Results are expressed as log10-
relative quantitation levels.
6 G.M. Nitulescu et al.accompanied by a decrease in the number of cells in the G0/G1
indicating mitotic inhibition, while the 4-aminopyrazolone
derivatives (4g–h) produced a slight decrease in G2/M. The
compound 4e induced a drastic increase in G2/M cell popula-
tions, accompanied by the reduction of cells in G0/G1 phase.
3.2.5. Expression of genes involved in cell cycle
We analyzed the effect of the synthesized substances on the
gene expression of cyclin A, cyclin B, CDK1 and CDC20 at
the level of mRNA expression in HT-29 cells after a 24 h expo-
sure. It was observed an increased expression of cyclin A,
cyclin B, CDK1 and CDC20 after treatment of cells with
50 lg/mL of 4e, which correlated with the sharp increase in
G2/M and thus associated with a blockage at this levelPlease cite this article in press as: Nitulescu, G.M. et al., Ultrasound-assisted synthes
Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.12.006(Fig. 5). Also, in case of 4b and 4f the increased expression
of cyclin A was associated with a mild G2/M arrest.
3.2.6. Expression of genes involved in xenobiotics metabolism
It is very important to evaluate the involvement of different
enzymes in the biotransformation reactions for drug detoxifi-
cation and/or bio-activation, taking into account that the
proper drug metabolism and elimination will avoid or diminish
the adverse effects.
NAT catalyzes the biotransformation of aromatic and hete-
rocyclic amines. These enzymes participate in both detoxifica-
tion and activation reactions, because NAT can facilitate the
detoxification of carcinogenic arylamines to harmless metabo-
lites by N-acetylation or promote their metabolic activation byis and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors.
Figure 4 HT-29 cells exposed for 24 h to 50 lg/mL of the new compounds. Evaluation of the cell cycle by flow cytometry and the
FlowJo 8.8.6 software.
Table 2 Percentage of HT-29 cell phases quantification after
24 h exposure to 50 lg/mL of the new compounds. Evaluation
by flow cytometry using the PI test.
Sample G0/G1 S G2/M
Control 65.81 22.49 10.03
4a 61.66 26.75 11.31
4b 62.35 19.78 21.41
4c 63.64 24.20 10.52
4d 64.11 26.47 10.75
4e 4.17 11.32 80.28
4f 54.02 25.32 22.57
4g 73.40 18.06 5.96
4h 66.67 21.65 8.35
Figure 5 The influence of the tested compounds on the exp
New pyrazole derivatives as cell cycle inhibitors 7
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NAT2 expression was inhibited in the presence of the 4b and
4h, and increased by 4f, 4a and 4c indicating that these last
compounds might be metabolized via NAT pathway (Fig. 6).
In the human genome, 57 genes encoding for cytochrome
P450 enzymes have been identified, out of which in xenobiotic
metabolism they are involved mainly those belonging to
CYP1, CYP2 and CYP3A families. Of these CYP1A2,
CYP2A6, CYP2C, CYP2D6, CYP2E1 and CYP3A are
involved in the metabolism of 90% of the drugs.
CYP3A4 is responsible for the metabolism of 50% of the
drugs, followed by 2D6, 2C9 and 1A2, which metabolize
25%, 15% and 5% respectively. CYP1A, 1B, 2A, 2B and 2E
catalyze the conversion of a large number of proto-toxinsression of genes involved in the cell cycle of HT-29 cells.
is and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors.
Figure 6 The influence of the tested compounds on the expression of genes involved in the xenobiotic metabolism.
8 G.M. Nitulescu et al.and carcinogenic substances in terminally reactive metabolites.
CYP1A2 is the predominant form of the enzyme CYP1A, its
substratum being represented by planar aromatic molecules.
All new pyrazole compounds showed increased expression of
CYP1A1. CYP2C19 oxidizes especially unionized acid mole-
cules and is inhibited in the presence of 4a–h compounds.
CYP3A4 is the major P450 isoform of 3A family, the typical
substratum of the CYP3A4 being represented by the highly
hydrophobic compounds. CYP3A4 expression is increased
by the treatment with the 4g and 4h (Fig. 6).
4. Conclusion
By combining the pyrazole ring and the thiourea moiety we designed
new compounds targeting the cell cycle kinases. We have described a
simple, rapid and accessible ultrasound-assisted method to obtain
these derivatives and confirmed their structures by IR and NMR spec-
troscopic analysis and elemental analytical data. The compounds 4e
and 4g present a modest apoptosis-inducing effect. Exposure of
THP-1 cells to the compounds at 50 lg/mL resulted in cell viability
decrease, but produced a small effect at concentrations under 25 lg/
mL.
The compound 4e induced a drastic increase in G2/M cell popula-
tion, accompanied by the reduction of cells in G0/G1 phase in HT-29
cells after exposure to 50 lg/mL. The cell blockade in G2/M was cor-
related with an increased expression of cyclin A, cyclin B, CDK1 and
CDC20 genes. The compound 4e displayed the best anti-proliferative
effect and emerged as the lead molecule for new pyrazole/thiourea
based derivatives.
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